BOLT (BOLT) Fair Value & Analysis
Healthcare · Market cap 24.2M ILA
Fair value as of: Jun 25, 2026
From 1 valuation models · updated 7 days ago
Fair value updated Jun 25, 2026 — revised from 17.11 ILA to 1.81 ILA (−89.4%) since Jun 24, 2026. Share price +15.7% over the past month.
Price vs Fair Value (12 months)
12‑month range 2.09 ILA – 5.89 ILA · fair‑value band 1.20 ILA – 2.26 ILA · the 3.70 ILA price screens above the 1.81 ILA fair value. As of Jun 25, 2026.
✦ Which stocks are undervalued right now? Check free Discover now →Analysis
BOLT (BOLT) currently trades at 3.70 ILA, while our model-based Fair Value estimate is 1.81 ILA — implying the stock looks roughly 51.1% overvalued today. We read business quality at 32/100 (below-average quality), in the Healthcare sector. Bear case: priced above our estimate, the market already discounts strong expectations. Bull case: above-average quality can justify a premium — the entry price still matters most (evidence: low).
Trailing-twelve-month revenue stands at 21.0K ILA. Revenue grew 25.0% year over year. It earns a return on equity of -48.4%. The balance sheet holds a net cash position of 3.2M ILA. Fundamentals as of Jun 25, 2026
Key figures & financial health
More key figures
Figures from reported company fundamentals (EODHD) · as of Jun 25, 2026. TTM = trailing twelve months.
Revenue & earnings trend
FY2021 – FY2025 · reported fiscal years
BOLT reported revenue of 0 ILA in FY2025 versus 3.0K ILA in FY2021. Reported net income was −11.7M ILA in FY2025.
Is BOLT fairly valued? → Check now
Similar stocks
6 more Biotechnology stocks, each showing price versus our Fair Value estimate (as of Jun 25, 2026).
| Stock | Price | Fair Value | vs Fair Value |
|---|---|---|---|
| Vertex Pharmaceuticals Incorporated VRTX | 7,746 MXN | 449.62 MXN | -94% |
| Regeneron Pharmaceuticals, Inc REGN | $601.65 | $577.20 | -4% |
| UCB SA UCB | €247.60 | €180.06 | -27% |
| argenx SE ARGNF | $900.00 | $382.64 | -57% |
| Alnylam Pharmaceuticals, Inc ALNY | $303.64 | $110.31 | -64% |
| Samsung Biologics Co 207940 | 1,000,000 KRW | 724,332 KRW | -28% |
Explore undervalued stocks
More undervalued Healthcare stocks →
Frequently asked questions
Is BOLT (BOLT) undervalued?
What is the fair value of BOLT?
What is the quality score of BOLT?
What is the revenue of BOLT (BOLT)?
What is the net profit margin of BOLT?
How we calculate Fair Value
Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data — nothing guessed.
Educational research only · not financial advice · no buy/sell recommendation. Model-based estimates are not certainties; their reliability depends on data quality and assumptions.